InspireMD Inc (NSPR)

NASDAQ
Currency in USD
2.300
-0.050(-2.13%)
Closed·
After Hours
2.399+0.099(+4.304%)
·
NSPR Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
NSPR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.2902.400
52 wk Range
1.9903.798
Key Statistics
Edit
Prev. Close
2.35
Open
2.33
Day's Range
2.29-2.4
52 wk Range
1.99-3.798
Volume
26.9K
Average Volume (3m)
159.05K
1-Year Change
-5.84%
Book Value / Share
0.95
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NSPR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.500
Upside
+95.65%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

InspireMD Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

InspireMD Inc Company Profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as well as treating acute stroke with tandem lesions. It has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Miami, Florida.

InspireMD Inc Earnings Call Summary for Q1/2025

  • InspireMD Q1 2025: EPS beat at -$0.22 vs -$0.31 forecast; revenue missed at $1.53M vs $1.79M expected; stock down 3.79% after-hours
  • Revenue up 1.2% YoY; net loss of $11.166M; strong liquidity with current ratio of 5.28x; Financial Health Score at 2.18 (Fair)
  • U.S. launch of CGuard Prime stent expected Q3 2025; FDA approval for CGuardians Two trial targeted H1 2026; Switchgard clearance late 2026
  • CEO optimistic about CGuard Prime's potential in carotid disease treatment; clinical trial enrollment progressing well
  • Risks: revenue shortfall, extended FDA timelines, ongoing net losses; analysts focused on approval delays and commercial strategy
Last Updated: 09/05/2025, 14:18
Read Full Transcript

Compare NSPR to Peers and Sector

Metrics to compare
NSPR
Peers
Sector
Relationship
P/E Ratio
−1.9x−14.0x−0.5x
PEG Ratio
0.290.070.00
Price/Book
2.5x2.1x2.6x
Price / LTM Sales
10.0x0.8x3.2x
Upside (Analyst Target)
91.5%86.4%45.3%
Fair Value Upside
Unlock19.6%7.4%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 4.500
(+95.65% Upside)

Earnings

Latest Release
May 09, 2025
EPS / Forecast
-0.22 / -0.31
Revenue / Forecast
1.53M / 1.79M
EPS Revisions
Last 90 days

NSPR Income Statement

People Also Watch

18.21
SRPT
-5.30%
95.32
DECK
-3.11%
2.650
ATAI
-2.57%
3.310
JSPR
-4.61%
42.980
SMR
+2.04%

FAQ

What Stock Exchange Does InspireMD Trade On?

InspireMD is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for InspireMD?

The stock symbol for InspireMD is "NSPR."

What Is the InspireMD Market Cap?

As of today, InspireMD market cap is 70.77M.

What Is InspireMD's Earnings Per Share (TTM)?

The InspireMD EPS (TTM) is -0.79.

When Is the Next InspireMD Earnings Date?

InspireMD will release its next earnings report on 11 Aug 2025.

From a Technical Analysis Perspective, Is NSPR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has InspireMD Stock Split?

InspireMD has split 6 times.

How Many Employees Does InspireMD Have?

InspireMD has 66 employees.

What is the current trading status of InspireMD (NSPR)?

As of 16 Jul 2025, InspireMD (NSPR) is trading at a price of 2.30, with a previous close of 2.35. The stock has fluctuated within a day range of 2.29 to 2.40, while its 52-week range spans from 1.99 to 3.80.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.